New gel could tackle stubborn yeast infections

NCT ID NCT07521137

Recruiting now Disease control Sponsor: Sano Chemicals Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new gel called OCF001 for treating acute yeast infections in women. About 36 women with a confirmed yeast infection will use the gel or a placebo for 7 days. Researchers will check if the infection clears up and if the gel is safe and well-tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OCF001 (occidiofungin) intravaginal gel
What this could lead to: If successful, this could provide a new topical treatment option for acute yeast infections, potentially helping women who don't respond to standard antifungals.
What could go wrong: This is an early Phase 2a trial with only 36 participants, so results may not apply to everyone. The gel may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates